TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03336736

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise
Description: The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise
Description: The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires.
Study: NCT01308203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release niacin/laropiprant
Description: Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
Study: NCT03084653

Intervention type: OTHER
Intervention: Survey
Description: Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
Study: NCT00818077

Intervention type: OTHER
Intervention: Continuous Glucose Monitoring of Carbohydrate Intake
Description: Subjects eat standard breakfast and lunch and keep food records.
Study: NCT01512017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crystalline cellulose simple occlusive dressing
Description: A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: External use
Study: NCT03577080

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ET+RT+ NMES
Description: Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ET+RT+ NMES
Description: Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
Study: NCT03974867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5Mg Tab
Description: Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg
Description: Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;
Study: NCT02464007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rSIFN-co
Description: Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
Study: NCT03350282

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GAA-creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine
Study: NCT03961737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsies
Description: Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients.
Study: NCT01164293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atopy patch test with food allergen
Description: Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
Study: NCT03125967

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Philips GoLite Blu HF3429/60
Description: Exposure to daily morning colored light in the 440-485 nm wavelength range

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Philips LivingColor Aura 70998/60/48
Description: Exposure to daily morning colored light in the 625-740 nm wavelength range
Study: NCT02188147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Term Wearable Defibrillator
Description: Short-term Wearable Defibrillator (SWD 1000)
Study: NCT00608101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
Study: NCT00740636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
Study: NCT03866889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: In the performance of the squat exercise (Back Squat), the subjects will be standing, with an Olympic bar behind their neck, supported on both trapezoids, while the hands will help to hold and stabilize the bar, taking it from below.~For hamstring curl, the subject will be in the prone position, clinging to the backrest, with the legs under the arm that lifts the weight.~The deadlift exercise will be performed from the standing posture, holding the bar with your arms extended and the trunk straight, while your hands will hold the bar at the height and separation of the hips.~Finally, in the quadriceps chair the subject will find himself sitting with his back straight and supported on the back of the seat, while the legs will go under the arm that lifts the weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal activity
Description: The subjects included in the control group will continue to perform the same strength training plan that they did before starting this one. The periodicity will be the same (4 days / week) and with the same intensity.
Study: NCT03992365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Description: The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl
Description: The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.
Study: NCT01499095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (Insulin glargine)
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
Study: NCT00113763

Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
Study: NCT00522730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Duration : 5 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Description: Duration : 5 days
Study: NCT01323517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab, Melphalan and Dactinomycin
Description: Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
Study: NCT00685217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT Secur (Gynecare)
Description: Sling device for stress urinary incontinence

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT (Gynecare)
Description: Sling procedure for stress urinary incontinence
Study: NCT03295292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: 50uL of commercially available fibrin sealant (Baxter, TISEEL)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: 50uL of commercially available fibrin sealant (Baxter, TISEEL)
Study: NCT03442114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroxyurea SDM Toolkit
Description: Implementation tools and visit decision aids

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Pocket Guide
Description: current hydroxyurea protocol and ASH pocket guide
Study: NCT01731639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSOME
Description: The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form \> 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
Study: NCT03015987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser activated irrigation
Description: diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diode laser activated irrigation
Description: diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
Study: NCT02346656

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study: NCT03517540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison with monotherapy and different combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison with monotherapy and different combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison with monotherapy and different combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Description: Comparison with monotherapy and different combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Description: Comparison with monotherapy and different combination doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Description: Comparison with monotherapy and different combination doses
Study: NCT02665793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBPCFC to peanut cookie

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBPCFC to peanut cookie

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose DBPCFC to peanut flour
Description: Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose DBPCFC to peanut flour
Description: Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
Study: NCT00769132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: niacin + laropiprant
Description: ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: niacin
Description: ER niacin 2 g tablet once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: laropiprant
Description: laropiprant 40 mg once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: matching placebo tablets for each of the interventions once daily for 7 days
Study: NCT01971099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tribulus terrestris
Description: patients will use 750mg/day of tribulus terrestris

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will take one pill a day (the same shape of the drug)
Study: NCT01065246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab
Description: 4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
Study: NCT03334942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child and Family Traumatic Stress Intervention
Description: The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
Study: NCT04220073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: JS005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01028274

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules, twice daily with meals for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product 1
Description: Two capsules, twice daily with meals for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product 2
Description: Two capsules, twice daily with meals for 12 weeks.
Study: NCT00698009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Infusion
Description: Natural Killer Cell Infusion on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses.
Study: NCT02742415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Hand Massage
Description: Caring Hand Massage is a hand massage therapy program with several steps and techniques.
Study: NCT00823680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5027838
Description: 200mg po qd for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5027838
Description: 50mg po bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: 400mg po bid for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: 10mg po bid for 4 weeks
Study: NCT02505841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP block with Ropivacaine
Description: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP block with Ropivacaine
Description: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curare
Description: Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curare
Description: Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
Study: NCT03586778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercise
Description: Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
Study: NCT01440608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose Zinc
Description: Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
Study: NCT00685763

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation and chemotherapy
Description: Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses